Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using finasteride and minoxidil for 11 months but is experiencing increased hair loss and no signs of improvement. Another user shares a similar experience and mentions iron deficiency and thyroid issues affecting hair loss despite using the treatments.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

The conversation is about a homemade hair loss treatment serum containing Procyanidin B2, Aloe Vera Gel, Coconut Oil, Castor Oil, and Rosemary Essential Oil. The main concern is finding an affordable source of Procyanidin B2 and ensuring its stability in the serum at room temperature.

The conversation is about alternatives to finasteride for hair loss, with suggestions including fluridil, oral minoxidil, alfatradiol, and cb-03-01. Concerns about finasteride's side effects, including potential breast cancer risk, are also discussed.

The conversation discusses the potential benefits and risks of using Methionine and Glycine for hair loss, with concerns about cancer risk if not balanced properly. The user seeks opinions on these amino acids for hair health and overall benefits.

The conversation discusses skepticism and mixed opinions about a hair loss theory, mentioning treatments like Minoxidil, finasteride, RU58841, and Procyanidin B2. There is criticism of a content creator named HairCafe and the difficulty in obtaining effective sulforaphane supplements.

Procapil is claimed to be better than Minoxidil for hair loss. Users discuss the effectiveness of various treatments, including Minoxidil, Finasteride, RU58841, and The Ordinary's Multi Peptide Hair Serum.

The user is experiencing significant hair shedding and suspects it may be due to low serum ferritin levels rather than worsening androgenetic alopecia. They have resumed iron supplementation and are seeking additional solutions to address the shedding.

A female user experienced hair loss after Covid and used Minoxidil 5% but saw more hair loss over time. She also uses alfatradiol, topical MSM, and betamethasone sporadically, and is unsure if Minoxidil is beneficial.

The conversation discusses the lack of in vivo studies on the effects of minoxidil and finasteride on human collagen and elastin after a year of use. It highlights the potential benefits of such research for understanding side effects and improving sales, despite challenges like cost and competition.

Creatine may contribute to hair loss in some individuals, even when using finasteride, minoxidil, and Nizoral. Despite mixed experiences, many users on the "big 3" report no significant hair loss from creatine, but individual results vary.

The conversation discusses concerns about using cordyceps while on dutasteride due to potential DHT increase, with OP experiencing hair loss after using creatine. OP is advised to stop creatine and give dutasteride more time to evaluate its effectiveness.

In this conversation, people discussed how Minoxidil and Finasteride can be toxic to cats if ingested. It was highlighted that even when being careful with application, there is still a risk of poisoning due to the potential for contact between fur/hair and the substances.

The user is experiencing significant hair regrowth with 5 mg oral minoxidil and 1 mg finasteride but also side effects like eye puffiness and hypertrichosis. They are considering reducing the minoxidil dose to 2.5 mg to lessen side effects and are curious about caffeine serums for eye puffiness.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.

The user is experiencing hair loss despite using 1 mg finasteride, 2.5 mg minoxidil, a multivitamin, and a topical finasteride-minoxidil solution. Suggestions include increasing minoxidil dosage, addressing vitamin deficiencies, especially Vitamin D, and considering lifestyle changes like diet and exercise.

Minoxidil is typically applied once daily, with some users opting for foam to minimize irritation. Users often combine it with finasteride or use oral minoxidil for improved results, while managing scalp irritation with ketoconazole or salicylic acid shampoos.

OP asks if face copper peptides from Sephora can be used on the scalp for hair benefits. User233 suggests AHK-CU is mainly for hair, but GHK-CU can also be used.

The conclusion of the conversation is that CosmeRna may not be an effective treatment for hair loss compared to topical minoxidil 2%. It is suggested to wait for more reviews before purchasing it.

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

The conversation is about different treatments for hair loss, including minoxidil, finasteride, RU58841, macroneedling, and pyrilutamice.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Oral minoxidil is causing significant blood pressure fluctuations and increased heart rate, leading the user to consider switching to topical minoxidil and tretinoin. The user plans to consult a cardiologist and is likely to stop using oral minoxidil.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

The conversation humorously discusses hair loss treatments like finasteride and minoxidil, noting minoxidil's toxicity to cats. It jokes about a lion needing hair restoration, with references to hair transplants in Turkey.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

The user discusses using compounded oral minoxidil due to the ineffectiveness and inconvenience of topical minoxidil for diffuse thinning. They question the efficacy of compounded minoxidil compared to original tablet forms and express concerns about the importance of excipients and binders.